Nisa Investment Advisors
VYNE icon

Nisa Investment Advisors’s VYNE Therapeutics VYNE Stock Holding History

Nisa Investment Advisors’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-28
Closed -$2 – 2334
2021
Q2 		$2 Hold
28
– – ﹤0.01% 2306
2021
Q1 		$3 Hold
28
– – ﹤0.01% 2281
2020
Q4 		$3K Buy
28
+16
+133% +$2.01K ﹤0.01% 2281
2020
Q3 		$1K Hold
12
– – ﹤0.01% 2244
2020
Q2 		$1K Sell
12
-176
-94% -$23.8K ﹤0.01% 2057
2020
Q1 		$36K Buy
+188
New +$59K ﹤0.01% 1602

Other funds holding VYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nisa Investment Advisors's VYNE Position: Q3 2021 in Review

Nisa Investment Advisors sold out of VYNE Therapeutics (VYNE) in Q3 2021, closing a stake of 28 shares — an estimated $2 sold.

Nisa Investment Advisors first reported a position in VYNE in Q1 2020 and held it in 6 quarters. The position peaked at $36K in Q1 2020. 64 funds tracked by Wall St. Rank hold VYNE as of Q3 2021.

  • Nisa Investment Advisors reported no remaining VYNE Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Nisa Investment Advisors sold 28 VYNE Therapeutics shares in Q3 2021, an estimated $2.
  • Nisa Investment Advisors first reported a position in VYNE Therapeutics in Q1 2020 and held it in 6 quarters.
  • Nisa Investment Advisors's VYNE Therapeutics position peaked at $36K in Q1 2020.
  • 64 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q3 2021.

Based on Nisa Investment Advisors's 13F filing for Q3 2021, filed 18 Oct 2021.